Abstract
Synthetic peptides corresponding to linear sequences of HLA class I molecules have profound immunomodulatory effects in vitro and in vivo. Recent clinical trials confirm their potential as the therapeutics for transplantation and for a variety of immune-mediated diseases. These peptides also inhibit NK responses in vivo in humans. The importance of the carboxy end of the alpha 1 alpha helix in negative signaling to both T cells and NK cells focuses attention on new targets for immunotherapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Clinical Trials as Topic
-
Graft Rejection / immunology
-
Graft Rejection / prevention & control*
-
HLA-A2 Antigen / chemistry
-
HLA-A2 Antigen / immunology
-
Histocompatibility Antigens Class I / chemistry
-
Histocompatibility Antigens Class I / immunology*
-
Humans
-
Immunotherapy / methods*
-
Killer Cells, Natural / immunology
-
Peptide Fragments / chemistry
-
Peptide Fragments / therapeutic use*
-
Protein Structure, Secondary
-
Receptors, Antigen, T-Cell / chemistry
-
Receptors, Antigen, T-Cell / immunology
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology*
Substances
-
HLA-A2 Antigen
-
Histocompatibility Antigens Class I
-
Peptide Fragments
-
Receptors, Antigen, T-Cell